Chinese Medical Journal (Jan 2023)
Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies
- Zhenan Deng,
- Meiling Jin,
- Changxing Ou,
- Wei Jiang,
- Jianping Zhao,
- Xiaoxia Liu,
- Shenghua Sun,
- Huaping Tang,
- Bei He,
- Shaoxi Cai,
- Ping Chen,
- Penghui Wu,
- Yujing Liu,
- Jian Kang,
- Yunhui Zhang,
- Mao Huang,
- Jinfu Xu,
- Kewu Huang,
- Qiang Li,
- Xiangyan Zhang,
- Xiuhua Fu,
- Changzheng Wang,
- Huahao Shen,
- Lei Zhu,
- Guochao Shi,
- Zhongmin Qiu,
- Zhongguang Wen,
- Xiaoyang Wei,
- Wei Gu,
- Chunhua Wei,
- Guangfa Wang,
- Ping Chen,
- Lixin Xie,
- Jiangtao Lin,
- Yuling Tang,
- Zhihai Han,
- Kian Fan Chung,
- Qingling Zhang,
- Nanshan Zhong,
- on behalf of the C-BIOPRED Consortium,
- Lishao Guo
Affiliations
- Zhenan Deng
- Meiling Jin
- Changxing Ou
- Wei Jiang
- Jianping Zhao
- Xiaoxia Liu
- Shenghua Sun
- Huaping Tang
- Bei He
- Shaoxi Cai
- Ping Chen
- Penghui Wu
- Yujing Liu
- Jian Kang
- Yunhui Zhang
- Mao Huang
- Jinfu Xu
- Kewu Huang
- Qiang Li
- Xiangyan Zhang
- Xiuhua Fu
- Changzheng Wang
- Huahao Shen
- Lei Zhu
- Guochao Shi
- Zhongmin Qiu
- Zhongguang Wen
- Xiaoyang Wei
- Wei Gu
- Chunhua Wei
- Guangfa Wang
- Ping Chen
- Lixin Xie
- Jiangtao Lin
- Yuling Tang
- Zhihai Han
- Kian Fan Chung
- Qingling Zhang
- Nanshan Zhong
- on behalf of the C-BIOPRED Consortium
- Lishao Guo
- DOI
- https://doi.org/10.1097/CM9.0000000000002556
- Journal volume & issue
-
Vol. 136,
no. 2
pp. 230 – 232
Abstract
No abstracts available.
